CDN Renal Pharmacology for Dialysis Nurses 1

Question 1

Which erythropoiesis-stimulating agent (ESA) is most commonly used to treat anemia of chronic kidney disease in dialysis patients?

Accepted Answer

Epoetin alfa

Answer

Epoetin alfa is the most widely used ESA for dialysis-associated anemia, stimulating bone marrow production of red blood cells.

Question 2

What hemoglobin range is targeted when using ESA therapy in dialysis patients according to KDIGO guidelines?

Accepted Answer

10–11.5 g/dL

Answer

KDIGO guidelines recommend targeting hemoglobin between 10–11.5 g/dL with ESA therapy to improve quality of life while avoiding the increased cardiovascular risks associated with higher levels.

Question 3

IV iron supplementation is indicated in dialysis patients when ferritin is below what threshold despite ESA therapy?

Accepted Answer

200 ng/mL

Answer

IV iron is commonly indicated when serum ferritin is below 200 ng/mL or transferrin saturation is below 20%, suggesting functional iron deficiency limiting ESA response.

Question 4

Which phosphate binder is safe to use in dialysis patients with hypercalcemia?

Accepted Answer

Sevelamer hydrochloride

Answer

Sevelamer is a non-calcium, non-aluminum phosphate binder that effectively lowers serum phosphorus without contributing to hypercalcemia.

Question 5

Cinacalcet (Sensipar) is used in dialysis patients primarily to treat which condition?

Accepted Answer

Secondary hyperparathyroidism with elevated PTH

Answer

Cinacalcet is a calcimimetic that increases the parathyroid gland's sensitivity to calcium, suppressing PTH secretion and treating secondary hyperparathyroidism.

CDN - Certified Dialysis Nurse Practice Test

CDN - Certified Dialysis Nurse Practice Test

CDN Renal Pharmacology for Dialysis Nurses 1